AGC to manufacture adjuvant for Novavax COVID-19 vaccine

By The Science Advisory Board staff writers

June 3, 2020 -- AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus vaccine candidate, NVX-CoV2373.

AGC will manufacture Matrix-M, the adjuvant component of the vaccine candidate that helps enhance the immune response and stimulate high levels of neutralizing antibodies. The vaccine candidate is a prefusion protein made using Novavax's proprietary nanoparticle technology.

AGC plans to optimize process development for rapid scale-up of Matrix-M to increase Novavax's capacity to deliver doses of the vaccine this year. Phase I clinical trial results for NVX-CoV2373 are expected in July.

Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer...
AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.
Codiak partners with Ragon Institue for SARS-CoV-2 vaccine platform
Codiak BioSciences has entered into a strategic collaboration with the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute...
Online tool tracks COVID-19 vaccine development
A new interactive online tool to track the progress of coronavirus vaccine candidates currently under development has been published by the University...
AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter